Clinical trials: Lp(A)
Cerebrovascular Accident
Transient Ischemic Attack (TIA) Triage and Evaluation of Stroke Risk
Transient ischemic attack (TIA) is a transient neurological deficit (speech disturbance, weakness…), caused by temporary occlusion of a brain vessel by a blood clot that leaves no lasting effect.
- Trial name
- NCT01423201
- Where
- 3 sites in United States
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- Stanford University
Cardiac Surgery
RECOVER I Impella RECOVER LP/LD 5.0 Support System Safety and Feasibility Study
To demonstrate that that the device is safe and potentially efficacious for use as a left ventricular cardiac assist device for postcardiotomy patients who require hemodynamic support post weaning from cardiopulmonary bypass.
- Trial name
- RECOVER I (NCT00596726)
- Testing
- IMPELLA LP/LD 5.0
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Abiomed Inc.
Recurrent Osteosarcoma
Single-Patient Expanded Access Protocol - RNA-LP in a Patient With Recurrent Osteosarcoma
Treatment of a patient with recurrent osteosarcoma with personalized pp65/tumor mRNA RNA-LP under an individual patient expanded access protocol.
- Trial name
- NCT07560709
- Testing
- pp65/tumor mRNA RNA-LP
- Where
- United States
- Sponsor
- University of Florida
Ischemic Stroke
Atherogenic Lipoproteins in Ischemic Stroke
Apolipoprotein B (apoB) levels (which encompass all atherogenic lipoproteins, including LDL), Lp(a) levels, and carotid IPH are associated with both first-ever and recurrent ischemic stroke.
- Trial name
- AGELESS (NCT05090878)
- Where
- 2 sites in Switzerland
- Volunteers
- 500 people
- Sponsor
- University Hospital, Basel, Switzerland
Angina, Stable, Inflammation
The Effect of Dan-shen Extract On Lipoprotein Associated PHospholipase A2 Levels IN Patients With Stable Angina Pectoris
This is a randomized, double-blind, placebo-controlled, adaptive clinical trial, which will assess the effect of DanshenDuofensuanyan[Danshen (a kind of Chinese herbal drug) extract] treatment on Lipoprotein associated…
- Trial name
- DOLPHIN (NCT02870764)
- Testing
- Dan-shen extract, Standard medical care
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Taizhou Fourth People's Hospital
Retinitis Pigmentosa
A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa
The main purpose of this study is to evaluate the preliminary safety and immunogenicity (ability of an antigen to provoke immune response in the human body) of CNTO 2476, administered subretinally, in participants with advanced…
- Trial name
- NCT00458575
- Testing
- CNTO 2476
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Centocor, Inc.
Familial Hypercholesterolemia, Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia
Atlantic Lipid Lowering Treatment Optimization Program
Hypercholesterolemia is recognized as the major driver for cardiovascular morbidity and mortality. To help address this in our community, Atlantic Medical Group (AMG) formed a lipid workgroup chaired by Robert D.
- Conditions
- Familial Hypercholesterolemia, Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia, Apolipoprotein B 100, Familial Defective, High Density Lipoprotein Deficiency
- Trial name
- ALLTOP (NCT06439654)
- Testing
- Supportive care
- Where
- 2 sites in United States
- Volunteers
- 250 people
- Sponsor
- Atlantic Health System
Acute Coronary Syndrome
The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g.
- Trial name
- SOLID-TIMI 52 (NCT01000727)
- Testing
- Darapladib 160 mg, Standard Therapy
- Where
- 914 sites in United States, Argentina and 34 more
- Volunteers
- 13,026 people
- Sponsor
- GlaxoSmithKline
COVID-19, SARS-COV-2 Infection
A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19
The purpose of this study is to learn about the safety, tolerability, and immunogenicity of an updated vaccine against COVID-19, called BNT162b2 (2025/2026 formulation).
- Trial name
- NCT07222384
- Testing
- BNT162b2 (2025/2026 formulation)
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 344 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Cardiovascular Disease and Lipoprotein(a)
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
This open-label extension study provides post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301).
- Trial name
- NCT07517263
- Testing
- Pelacarsen (TQJ230)
- Where
- 646 sites in United States, Argentina and 38 more
- Volunteers
- 5,700 people
- Sponsor
- Novartis Pharmaceuticals
Ovarian Cancer, Breast Cancer
A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer
This is a two-way crossover bioequivalence study between test and reference product in patients diagnosed with BRCA mutated ovarian cancer, recurrent ovarian cancer or metastatic breast cancer.
- Trial name
- NCT05258747
- Testing
- Olaparib tablets, 150 mg, Lynparza® (olaparib) tablets 150 mg
- Where
- India
- Volunteers
- 70 people
- Sponsor
- Sandoz
Aortic Stenosis
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
The purpose of this study is to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis.
- Trial name
- NCT05646381
- Testing
- Pelacarsen (TQJ230) 80mg
- Where
- 140 sites in United States, Austria and 13 more
- Volunteers
- 502 people
- Sponsor
- Novartis Pharmaceuticals
Persistent Asthma
Indoor Air Quality Asthma Study: The Effect of Indoor Air Quality and Mitigation of Same on Persistent Asthma
The primary objective is to determine whether continuous sensing, control and mitigation of home indoor air quality influences the frequency of asthma related symptoms, as measured by Serum IgE, Spirometry with exhaled Nitric…
- Trial name
- IAQ (NCT05843045)
- Testing
- Indoor Air Quality Mitigation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Dayton Children's Hospital
Fed
Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fed Conditions
This is a randomized, open Label, balanced, two-treatment, two-period, two-sequence, single dose, cross over pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding…
- Trial name
- NCT01827878
- Testing
- Lisinopril and Hydrochlorothiazide Tablets (20+25) mg, Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- IPCA Laboratories Ltd.
Hyperlipidemia, Elevated Lp(a)
2-HOBA Supplementation in People With Elevated Lipoprotein(a)
The goal of this clinical trial is to learn if a natural supplement called 2-hydroxybenzylamine (2-HOBA) can reduce harmful oxidized lipids and improve the function of lipoprotein(a) in adults with high lipoprotein(a) levels.
- Trial name
- NCT07198009
- Testing
- 2-HOBA (Hobamine)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The Miriam Hospital
Healthy, Heart Disease
Family Research Study: Metabolism of Fats and Proteins in Specific Ethnic Groups
The purpose of this study is to determine whether lipoprotein(a), also called Lp(a), is a risk factor for cardiovascular (heart) disease. Lipoproteins are tiny particles that circulate in the blood.
- Trial name
- NCT00853775
- Testing
- No intervention, observational study
- Where
- United States
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Congenital Hyperinsulinism
Sandostatine® LP and Hyperinsulinism
To replace Sandostatine® in three daily subcutaneous injections by a single intramuscular injection of Sandostatine® LP per month in patients with a diffuse form of hyperinsulinism.
- Trial name
- NCT00987168
- Testing
- Sandostatine LP
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
POAF, Atrial Fibrillation (AF)
Association of Lipoprotein(a) With Postoperative Atrial Fibrillation
About one in three patients who undergo open-heart surgery develop an irregular heart rhythm called postoperative atrial fibrillation (POAF).
- Trial name
- LPa and POAF (NCT07737444)
- Volunteers
- 20 people
- Sponsor
- Anthony Tang
Acute Chest Syndrome
ST Elevation in Acute Chest Pain; Could Measurement of Lipoprotein-associated Phospholipase A2 (Lp-PLA2) be Helpful to the Clinician?
A blood test (2-3 cc peripheral venous blood) drawn /used from already available required lab tests to distinguish between pericarditis accompanied with electrocardiogram (ECG) signs mimicking infarction.
- Trial name
- NCT01041339
- Where
- Israel
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Alexhander Izhaki
Abdominal Aortic Aneurysm
Study of the Endovascular QUANTUM LP™ Stent Graft System in Abdominal Aortic Aneurysms (AAA)
The objective of this clinical study is to assess the safety and effectiveness of the Cordis Endovascular Quantum LP™ Stent Graft System.
- Trial name
- NCT00233688
- Testing
- QUANTUM LP™ STENT GRAFT SYSTEM, Open surgical repair
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Cordis US Corp.